Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | LSS | P48449 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 9/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 3/20 | 0.39 |
| ▸ | CES1 | P23141 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8143768 | 0.87 | CA2 (0.50) | CA2LSSCA1DNM1HTT | |
| SCHEMBL9618276 | 0.87 | CES2 (0.41) | CA2HTTCES2 | |
| SCHEMBL31019233 | 0.84 | GPR84 (0.43) | CA2LSS | |
| SCHEMBL4661753 | 0.80 | CA2 (0.50) | CA2CA1CES2CES1 | |
| SCHEMBL3859153 | 0.79 | CA1 (0.47) | CA2LSSCA1DNM1HTT | |
| Cadaverine Tartrate SCHEMBL4447979 | 0.76 | CA1 (0.44) | CA2LSSCA1DNM1HTT | |
| Cadaverine Tartrate SCHEMBL4443631 | 0.76 | CA1 (0.44) | CA2LSSCA1DNM1HTT | |
| SCHEMBL11497003 | 0.75 | CA1 (0.43) | CA2LSSCA1DNM1HTT | |
| Acetic Acid SCHEMBL29078335 | 0.75 | LSS (0.39) | CA2LSSDNM1HTTBBOX1 | |
| Acetic Acid SCHEMBL29078322 | 0.75 | LSS (0.39) | CA2LSSDNM1HTTBBOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025027019-A1 | METHOD OF DETERMINING NUCLEIC ACID CONCENTRATION IN AQUEOUS SOLUTION OR DISPERSION | BioNTech SE (DE) | 2025-02-06 | — | — | WO | claimed |
| US-10732179-B2 | Method for detecting Staphylococcus contained in milk | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-08-04 | — | — | US | claimed |
| US-20190079089-A1 | METHOD FOR DETECTING STAPHYLOCOCCUS CONTAINED IN MILK | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2019-03-14 | — | — | US | claimed |
| US-10151751-B2 | Method for detecting Staphylococcus contained in milk | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-12-11 | — | — | US | claimed |
| EP-3085770-B1 | METHOD FOR DETECTING STAPHYLOCOCCI IN MILK | ASAHI CHEMICAL IND (JP) | 2018-11-07 | — | — | EP | claimed |
| US-20160313327-A1 | METHOD FOR DETECTING STAPHYLOCOCCUS CONTAINED IN MILK | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2016-10-27 | — | — | US | claimed |
| EP-3085770-A1 | METHOD FOR DETECTING STAPHYLOCOCCI IN MILK | Asahi Kasei Kabushiki Kaisha (JP) | 2016-10-26 | — | — | EP | claimed |
| US-6989195-B2 | Coated particles, methods of making and using | LYOTROPIC THERAPEUTICS, INC. (US) | 2006-01-24 | — | — | US | claimed |
| US-20040201117-A1 | COATED PARTICLES, METHODS OF MAKING AND USING | ANDERSON DAVID (US) | 2004-10-14 | — | — | US | claimed |
| JP-62119234-A | — | — | None | — | — | JP | disclosed |
| US-12628492-B2 | Methods for improving perovskite solar cells | Alliance for Energy Innovation, LLC (US) | 2026-05-12 | — | — | US | disclosed |
| CN-121586781-A | Method for determining the concentration of nucleic acids in aqueous solutions or aqueous dispersions | 百欧恩泰欧洲股份公司 | 2026-02-27 | — | — | CN | disclosed |
| WO-2025027019-A1 | METHOD OF DETERMINING NUCLEIC ACID CONCENTRATION IN AQUEOUS SOLUTION OR DISPERSION | BioNTech SE (DE) | 2025-02-06 | — | — | WO | disclosed |
| US-20240315062-A1 | METHODS FOR IMPROVING PEROVSKITE SOLAR CELLS | Alliance for Energy Innovation, LLC | 2024-09-19 | — | — | US | disclosed |
| WO-2003000236-A1 | PARTICLES WITH IMPROVED SOLUBILIZATION CAPACITY | LYOTROPIC THERAPEUTICS, INC (US) | 2003-01-03 | — | — | WO | disclosed |
| US-6482517-B1 | Coated particles, methods of making and using | SELECT RELEASE, L.C. | 2002-11-19 | — | — | US | disclosed |
| US-20020102280-A1 | Solvent systems for pharmaceutical agents | LYOTROPIC THERAPEUTICS, INC. | 2002-08-01 | — | — | US | disclosed |
| JP-S62119234-A | ACRYLIC RESIN PLATE PROVIDED WITH ANTISTATIC PROPERTY | ASAHI CHEM IND CO LTD | 1987-05-30 | — | — | JP | disclosed |
| US-4364837-A | SUPERIOR FOAMING PROPERTIES AND STABILITY | LEVER BROTHERS COMPANY (US) | 1982-12-21 | — | — | US | disclosed |
| US-3964500-A | Lusterizing shampoo containing a polysiloxane and a hair-bodying agent | LEVER BROTHERS COMPANY (US) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12628492-B2 | Methods for improving perovskite solar cells | CA2, EPCAM, HAO2 | CA2 1/4885LSS 2849/4885CA1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.